Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor Against Human Acute Myelogenous Leukemia Cells
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-13-0770
Full Text
Open PDFAbstract
Available in full text
Date
January 16, 2014
Authors
Publisher
American Association for Cancer Research (AACR)